Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953797 | 0.81 | RAB9A (0.62) | CA1CA2CA9RAB9ANPC1 | |
| SCHEMBL7013927 | 0.81 | ALDH1A1 (0.52) | RAB9ANPC1POLBMAPTAKR1C3 | |
| SCHEMBL6108998 | 0.79 | HDAC1 (0.55) | CA1CA2CA9RAB9ANPC1 | |
| SCHEMBL7058277 | 0.79 | CA1 (0.54) | CA1CA2CA9RAB9ANPC1 | |
| SCHEMBL7061559 | 0.79 | CA1 (0.55) | CA1CA2CA9RAB9ANPC1 | |
| SCHEMBL5775229 | 0.79 | CA1 (0.41) | CA1CA2CA9RAB9AMAPT | |
| SCHEMBL15982252 | 0.78 | ALDH1A1 (0.38) | RAB9AALDH1A1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL10852754 | 0.78 | CA1 (0.60) | CA1CA2CA9RAB9ANPC1 | |
| SCHEMBL7796217 | 0.78 | KDM4E (0.61) | RAB9ANPC1POLBMAPTAKR1C3 | |
| SCHEMBL7215753 | 0.77 | ALDH1A1 (0.52) | RAB9ANPC1POLBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-10131640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2018-11-20 | — | — | US | disclosed |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2016-05-19 | — | — | US | disclosed |
| US-9238640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2016-01-19 | — | — | US | disclosed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| US-6624153-B2 | Derivatives of two synthetic anti-tuberculosis agents, thioacetazone and p-aminosalicylic acid, have been synthesized. In general, the halogenated compound has the structure of Structure I:for use as anti-tuberculosis | UNIVERSITY OF SCIENCES IN PHILADELPHIA | 2003-09-23 | — | — | US | disclosed |
| US-20030114531-A1 | Halogenated antituberculosis agents | KOBARFARD FARZAD (US) | 2003-06-19 | — | — | US | disclosed |
| WO-2002092019-A2 | HALOGENATED ANTITUBERCULOSIS AGENTS | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020173548-A1 | HALOGENATED ANTITUBERCULOSIS AGENTS | SCIENCES IN PHILADELPHIA, UNIVERSITY OF | 2002-11-21 | — | — | US | disclosed |
| US-6482982-B1 | BACTERICIDES; MYCOBACTERIUM RESISTANCE | UNIVERSITY OF SCIENCES OF PHILADELPHIA | 2002-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | CA1 4101/4885CA2 4588/4885CA9 3896/4885 |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | CA1 4219/4885CA2 4599/4885CA9 3872/4885 |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | CA1 4650/4885CA2 4474/4885CA9 4750/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | CA1 4101/4885CA2 4588/4885CA9 3896/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | CA1 4101/4885CA2 4588/4885CA9 3896/4885 |
| US-10131640-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | CA1 4101/4885CA2 4588/4885CA9 3896/4885 |
| US-20030114531-A1 | Halogenated antituberculosis agents | XDH, TST, QSOX1 | CA1 3534/4885CA2 2193/4885CA9 3740/4885 |
| US-20020173548-A1 | HALOGENATED ANTITUBERCULOSIS AGENTS | XDH, TST, QSOX1 | CA1 3534/4885CA2 2193/4885CA9 3740/4885 |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | CA1 4219/4885CA2 4599/4885CA9 3872/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | CA1 4219/4885CA2 4599/4885CA9 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.